tirzepatide vs semaglutide Vs. For Weight Loss – Forbes Health Tirzepatide vs Semaglutide: A Weight

My portion control has improved, and my snacking is minimal

spending on GLP-1s soared: total annual spending reached nearly $72 billion in 2023 ( [20] ) and climbed to approximately $52.7 billion in US market revenue in 2025 (accounting for 75.3% of the global GLP-1 market), with projections pointing toward $155.9 billion by 2033 ( [21] )

Frailty in individuals may include at least three of the following symptoms: unintentional weight loss, exhaustion (poor endurance), weakness (low grip strength), slowness, and physical inactivity (115)

This comparison is important because patients want more than just facts about which medicine seems stronger